Filing search / Ownership / Nkarta, Inc. / Page 3

8-K

3h19a

16 Mar 23

Nkarta Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights

4:09pm

8-K

r62 zydrtjn8

9 Jan 23

Regulation FD Disclosure

4:48pm

S-8

45zn nan5q2xow4i

9 Jan 23

Registration of securities for employees

4:14pm

8-K

dgw5t dpnlwkg

5 Dec 22

Regulation FD Disclosure

7:39am

8-K

7c4rqr za2tfuf8wnk5w

2 Dec 22

Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX019

4:08pm

8-K

0v1ttyq7o 4xz20sntt

9 Nov 22

Nkarta Reports Third Quarter 2022 Financial Results and Corporate Highlights

4:03pm

8-K

n68h3foq67ttd9

11 Aug 22

Nkarta Reports Second Quarter 2022 Financial Results and Corporate Highlights

4:10pm

8-K

xoh4mgikxg5fqo

10 Jun 22

Submission of Matters to a Vote of Security Holders

4:15pm

8-K

t9yayk0q8

16 May 22

Nkarta Appoints David R. Shook, MD, as Vice President, Clinical Development

4:09pm

8-K

wb48hz1zn7

12 May 22

Nkarta Reports First Quarter 2022 Financial Results and Corporate Highlights

4:09pm

8-K

nhoej9

28 Apr 22

Other Events

4:20pm

424B5

93ypu1gl5f1 kojb

26 Apr 22

Prospectus supplement for primary offering

4:02pm

424B5

qh9rzrtuk

25 Apr 22

Prospectus supplement for primary offering

4:03pm

8-K

o5hp6

25 Apr 22

Nkarta Announces Positive Preliminary Dose Finding Data for Two Lead Engineered Natural Killer Cell Programs

7:52am

8-K

n37sth6bjtd z6

22 Apr 22

Nkarta to Host Conference Call Highlighting Preliminary Clinical Data from

4:17pm